According to the official website of the U.S. FDA, on June 5, the FDA released the final application materials for the renewal of the Modified Risk Tobacco Product (MRTP) order for Swedish Match U.S.A., Inc.'s General Snus product and announced the deadline for public comments. Public comments must be submitted to the docket by 11:59 PM Eastern Daylight Time on July 5, 2024, to ensure that the FDA can consider these opinions.
The application materials have been edited in accordance with applicable laws and can be found on the FDA website. Before making a final decision on the MRTP application, the FDA will consider all available information, including public comments and recommendations from the Tobacco Products Scientific Advisory Committee (TPSAC).
The FDA recently announced that the TPSAC meeting will be held on June 26, 2024 to discuss these renewal applications. The public can participate in person or online. Written submissions can be sent to the contact person by June 20, 2024. Individuals wishing to make a formal oral presentation should notify the contact person by 5 p.m. (Eastern Daylight Time) on June 11, 2024.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
